Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred patients on chronic haemodialysis were studied prospectively over one year for evidence of hepatitis and of infection with hepatitis A or B virus. Five patients developed transient elevations of SGPT, accompanied by a consistent pattern of clinical manifestations, including low-grade fever, anorexia, nausea, hepatomegaly, and hypotension during dialysis. None of these patients had a positive test for A or B virus infection. Non-A non-B hepatitis appears to cause a specific syndrome in uraemic patients, and its transmission in a dialysis unit seems unrelated to blood transfusions.
Proc Eur Dial Transplant Assoc 1979
PMID:Non-A, non-B hepatitis: a new syndrome in uraemic patients. 12 59

The 'e antigen' (eAg) is specifically associated with hepatitis B virus infections and appears to be a marker for the infectivity and a prognostic indicator of the chronicity of liver disease. Therefore we examined by immunodiffusion the presence of eAg in the seum of HBsAg-positive patients on maintenance dialysis. The dialysis patients had a significantly higher incidence of positive eAg compared with a group of unselected HBsAg-positive patients without renal failure. In most of the dialysis patients the microscopic findings in the liver revealed only 'minimal changes'. Three eAg-positive patients received a renal transplant. Afterwards they displayed an appreciably increased eAg-yield on immunodiffusion and histology revealed chronic persistent hepatitis. It is assumed therefore that the immunodeficiency of patients undergoing chronic haemodialysis is possibly a supporting factor in the synthesis of eAg, and will perhaps induce a more subscute and prolonged course of hepatitis. The synthesis of eAg after renal transplantation may be enhanced by the additional immunosuppressive therapy.
Proc Eur Dial Transplant Assoc 1978
PMID:E antigen in the serum of HBs antigen-positive patients on maintenance dialysis and after transplantation. 36 77

Advantages of home hemodialysis over center include better patient survival and rehabilitation, more patient convenience, decreased risk of hepatitis, and cheaper costs. Home dialysis places stress on the family and requires a great time commitment of the helper. Ninety-three patients began home dialysis training at our institution. Seventy-eight successfully completed training and five patients are still in training. Of the seventy-eight who completed training, fifty (64%) are still performing home dialysis for periods of from one month to 6 1/2 years. 10% received a kidney transplant, 13% died, and 13% have returned to a center for dialysis. Family stress was the major reason for return to a center in the ten patients who chose to do so. Even though home dialysis is superior to center dialysis, the percentage of patients being treated in the home in this country is diminishing. Possible reasons for this decline are discussed.
J Dial 1977
PMID:Whatever happened to home hemodialysis? 60 63

Eighteen patients received CP substituting AZ after renal transplantation following evidence of hepatitis. We have compared graft evolution before and after treatment with CP. Twelve patients showed no modification in graft evolution. In four patients the renal function decreased but it did not seem attributable to the change of the drug. Two patients showed intolerance attributable to the change of the drug. In one patient who received CP instead of AZ since the data of the transplant onwards, with no evidence of hepatic lesion, renal function decreased but this did not seem attributable to the use of the drug. The dose of CP in renal transplantation is discussed. We conclude that CP is a good substitute for AZ in renal transplanted patients. Adequate doses seemed to range between 0.7 and 1 mg/kg/day.
Proc Eur Dial Transplant Assoc 1976
PMID:Cyclophosphamide (CP) substituting azathioprine after renal transplantation. 77 35

Cartridge re-use is now successful in centre and home haemodialysis. The economic advantage of re-use is remarkable even in the case of a single re-use. However, hepatitis and pyrogenic reactions may follow re-use and are a source of possible contamination. The problem of storing sterilised cartridges also arises. In order to reduce the work load and simplify preparation and re-use the authors have developed a simple 'personal monitor' that permits automatic recovery of the cartridge and eliminates handling. In our unit this 'personal monitor' has been used for 14 months without complications and with considerable saving. By using the same cartridge three times for each patient, the aim of a 'weekly kidney' has been achieved.
Proc Eur Dial Transplant Assoc 1976
PMID:Weekly artificial kidney: personal monitor with cartridge re-use. 93 36

1. Fifteen percent of the hemodialysis patients were carriers of HBsAg. 2. Thirty-one percent of the carriers' contacts had HBAb in their blood. 3. Spouse of carriers had a higher prevalence of positive HBAb than any other family contact. 4. Only 6 out of 17 patients transmitted the virus to their contacts. 5. None of the contacts of the staff, with history of hepatitis B, had evidence of hepatitis. 6. Contacts with positive HBAb had no evidence of active liver disease.
Proc Clin Dial Transplant Forum
PMID:Nonpercutaneous transmission of hepatitis B to the families of hemodialysis patients. 102 90

From November, 1972 to November, 1974 the members of the team of a haemodialysis unit were systematically given Australia antigen immunoglobulin protection. Only one case of hepatitis occurred among the 53 members treated. The value of the antibody is discussed.
Proc Eur Dial Transplant Assoc 1975
PMID:An attempt to prevent hepatitis B in a haemodialysis unit's team utilisation of specific immunoglobulins. 119 59

Hepatitis C (HC) has been recently diagnosed by determination of specific antibodies that represent the former so-called non-A, non-B hepatitis. We studied the prevalence of plasma HCV antibodies among 61 unselected patients on hemodialysis (HD) and 43 on continuous ambulatory peritoneal dialysis (CAPD). Plasma C-antibodies were determined through the ELISA test system. Transfusion policy was the same in both groups. The prevalence of hepatitis C virus antibodies was significantly higher in hemodialysis patients than among those on CAPD. Time on dialysis, previous blood transfusions, and renal transplantation seem to increase the prevalence of C hepatitis antibodies among hemodialysis patients. The effect of these parameters on CAPD was smaller. Understanding the reasons for these differences may help prevent this disease among dialysis patients.
Perit Dial Int 1992
PMID:Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center. 154 76

Fifty-two patients on regular haemodialysis at our institution were evaluated for the presence of HCV infection. Evaluation included detailed history, clinical examination, and monthly screening for anti-HCV antibody, liver enzymes (ALT, AST), serum iron and ferritin. Also, three-monthly screening for other viral markers, HBV (HBsAg, HBsAb, HBcAb), CMV (IgG and IgM), EBV, and HIV. Anti-HCV antibody was found in 21 patients (40.4%). There was a significant (P less than 0.05) relationship between presence of anti-HCV antibody and proportion of patients who received blood transfusion. During a 12-month follow-up, four (11.4%) patients seroconverted to be Anti-HCV positive while one case (4.8%) seroconverted to be anti-HCV negative. The frequency of elevation of liver enzymes was significantly higher in Anti-HCV positive cases (14/18) than in negative cases (11/28, P = 0.01). Evaluation of liver biopsies of 13 patients showed chronic persistent hepatitis in six and chronic active hepatitis in seven cases. We concluded that hepatitis C is a common problem among chronic haemodialysis patients at our institution; HCV infection is documented in 70% of all clinically diagnosed NANB hepatitis. Presence of anti-HCV antibodies cannot differentiate between active and past infection and cases with early HCV infection can be missed when relying on the mere detection of anti-HCV antibodies.
Nephrol Dial Transplant 1992
PMID:Hepatitis C virus infection in chronic haemodialysis patients, a clinicopathologic study. 128 48

Non-A Non-B hepatitis (NANBH) is nowadays one of the most common causes of hepatic dysfunction in dialysis patients. We reviewed the records of 231 HBsAg-negative patients in our unit and found 119 patients with biochemical criteria of NANBH (51.5%), 88 of them (68.9%) with circulating antibodies against HCV (chi 2 P less than 0.0001). Such high prevalence of NANBH was due to an outbreak of NANBH in the late 70s and early 80s. Time on haemodialysis (HD) was the major risk factor of NANBH in this population, and no other risk factors were identified. Prevalence of anti-HCV was similar to reports from non-uraemic populations. Anti-HCV seems to be a reliable test to confirm NANBH, but not better than using common biochemical criteria of NANBH to manage these patients in dialysis units.
Nephrol Dial Transplant 1992
PMID:Prevalence of non-A non-B hepatitis and anti-HCV antibodies in a Portuguese dialysis population. 138 74


1 2 3 4 5 Next >>